Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
Times Cited: 485
Times Cited: 485
Times Cited
Times Co-cited
Similarity
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
63
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
51
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
41
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
39
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
37
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths. JAMA Psychiatry 2021
Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths. JAMA Psychiatry 2021
35
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano, Roland R Griffiths. J Psychopharmacol 2014
34
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
R R Griffiths, W A Richards, U McCann, R Jesse. Psychopharmacology (Berl) 2006
R R Griffiths, W A Richards, U McCann, R Jesse. Psychopharmacology (Berl) 2006
33
Trial of Psilocybin versus Escitalopram for Depression.
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt. N Engl J Med 2021
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt. N Engl J Med 2021
32
Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
30
Human hallucinogen research: guidelines for safety.
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
Mw Johnson, Wa Richards, Rr Griffiths. J Psychopharmacol 2008
28
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.
Leor Roseman, David J Nutt, Robin L Carhart-Harris. Front Pharmacol 2018
Leor Roseman, David J Nutt, Robin L Carhart-Harris. Front Pharmacol 2018
27
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Una McCann, Robert Jesse. Psychopharmacology (Berl) 2011
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Una McCann, Robert Jesse. Psychopharmacology (Berl) 2011
27
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C Andrade, Morgana M Novaes, Jessica A Pessoa, Sergio A Mota-Rolim, Flávia L Osório, Rafael Sanches, Rafael G Dos Santos,[...]. Psychol Med 2019
25
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
Peter Gasser, Dominique Holstein, Yvonne Michel, Rick Doblin, Berra Yazar-Klosinski, Torsten Passie, Rudolf Brenneisen. J Nerv Ment Dis 2014
25
Long-term follow-up of psilocybin-facilitated smoking cessation.
Matthew W Johnson, Albert Garcia-Romeu, Roland R Griffiths. Am J Drug Alcohol Abuse 2017
Matthew W Johnson, Albert Garcia-Romeu, Roland R Griffiths. Am J Drug Alcohol Abuse 2017
25
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu, Roland R Griffiths, Matthew W Johnson. Curr Drug Abuse Rev 2014
Albert Garcia-Romeu, Roland R Griffiths, Matthew W Johnson. Curr Drug Abuse Rev 2014
24
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
Francisco A Moreno, Christopher B Wiegand, E Keolani Taitano, Pedro L Delgado. J Clin Psychiatry 2006
23
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
22
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.
Robin L Carhart-Harris, David Erritzoe, Tim Williams, James M Stone, Laurence J Reed, Alessandro Colasanti, Robin J Tyacke, Robert Leech, Andrea L Malizia, Kevin Murphy,[...]. Proc Natl Acad Sci U S A 2012
Robin L Carhart-Harris, David Erritzoe, Tim Williams, James M Stone, Laurence J Reed, Alessandro Colasanti, Robin J Tyacke, Robert Leech, Andrea L Malizia, Kevin Murphy,[...]. Proc Natl Acad Sci U S A 2012
20
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Frederick S Barrett, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2015
Frederick S Barrett, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2015
19
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Gabrielle I Agin-Liebes, Tara Malone, Matthew M Yalch, Sarah E Mennenga, K Linnae Ponté, Jeffrey Guss, Anthony P Bossis, Jim Grigsby, Stacy Fischer, Stephen Ross. J Psychopharmacol 2020
Gabrielle I Agin-Liebes, Tara Malone, Matthew M Yalch, Sarah E Mennenga, K Linnae Ponté, Jeffrey Guss, Anthony P Bossis, Jim Grigsby, Stacy Fischer, Stephen Ross. J Psychopharmacol 2020
30
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Erich Studerus, Michael Kometer, Felix Hasler, Franz X Vollenweider. J Psychopharmacol 2011
Erich Studerus, Michael Kometer, Felix Hasler, Franz X Vollenweider. J Psychopharmacol 2011
18
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer,[...]. Neuropsychopharmacology 2019
Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer,[...]. Neuropsychopharmacology 2019
21
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
Peter Gasser, Katharina Kirchner, Torsten Passie. J Psychopharmacol 2015
Peter Gasser, Katharina Kirchner, Torsten Passie. J Psychopharmacol 2015
18
Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology.
Ido Hartogsohn. J Psychopharmacol 2016
Ido Hartogsohn. J Psychopharmacol 2016
18
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
Katherine A MacLean, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2011
16
The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
15
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Matthew W Johnson, Roland R Griffiths, Peter S Hendricks, Jack E Henningfield. Neuropharmacology 2018
Matthew W Johnson, Roland R Griffiths, Peter S Hendricks, Jack E Henningfield. Neuropharmacology 2018
18
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
R L Carhart-Harris, K J Friston. Pharmacol Rev 2019
R L Carhart-Harris, K J Friston. Pharmacol Rev 2019
15
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
Roland R Griffiths, Matthew W Johnson, William A Richards, Brian D Richards, Robert Jesse, Katherine A MacLean, Frederick S Barrett, Mary P Cosimano, Maggie A Klinedinst. J Psychopharmacol 2018
15
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell,[...]. EClinicalMedicine 2020
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell,[...]. EClinicalMedicine 2020
38
Cessation and reduction in alcohol consumption and misuse after psychedelic use.
Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2019
Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2019
27
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.
Felix Hasler, Ulrike Grimberg, Marco A Benz, Theo Huber, Franz X Vollenweider. Psychopharmacology (Berl) 2004
Felix Hasler, Ulrike Grimberg, Marco A Benz, Theo Huber, Franz X Vollenweider. Psychopharmacology (Berl) 2004
14
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Rr Griffiths, Wa Richards, Mw Johnson, Ud McCann, R Jesse. J Psychopharmacol 2008
Rr Griffiths, Wa Richards, Mw Johnson, Ud McCann, R Jesse. J Psychopharmacol 2008
14
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
Tehseen Noorani, Albert Garcia-Romeu, Thomas C Swift, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2018
Tehseen Noorani, Albert Garcia-Romeu, Thomas C Swift, Roland R Griffiths, Matthew W Johnson. J Psychopharmacol 2018
29
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.
Teri S Krebs, Pål-Ørjan Johansen. J Psychopharmacol 2012
Teri S Krebs, Pål-Ørjan Johansen. J Psychopharmacol 2012
13
The pharmacology of psilocybin.
Torsten Passie, Juergen Seifert, Udo Schneider, Hinderk M Emrich. Addict Biol 2002
Torsten Passie, Juergen Seifert, Udo Schneider, Hinderk M Emrich. Addict Biol 2002
13
Psychedelics and the essential importance of context.
Robin L Carhart-Harris, Leor Roseman, Eline Haijen, David Erritzoe, Rosalind Watts, Igor Branchi, Mendel Kaelen. J Psychopharmacol 2018
Robin L Carhart-Harris, Leor Roseman, Eline Haijen, David Erritzoe, Rosalind Watts, Igor Branchi, Mendel Kaelen. J Psychopharmacol 2018
13
Psychedelics and Psychedelic-Assisted Psychotherapy.
Collin M Reiff, Elon E Richman, Charles B Nemeroff, Linda L Carpenter, Alik S Widge, Carolyn I Rodriguez, Ned H Kalin, William M McDonald. Am J Psychiatry 2020
Collin M Reiff, Elon E Richman, Charles B Nemeroff, Linda L Carpenter, Alik S Widge, Carolyn I Rodriguez, Ned H Kalin, William M McDonald. Am J Psychiatry 2020
15
Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Friederike Holze, Patrick Vizeli, Laura Ley, Felix Müller, Patrick Dolder, Melanie Stocker, Urs Duthaler, Nimmy Varghese, Anne Eckert, Stefan Borgwardt,[...]. Neuropsychopharmacology 2021
Friederike Holze, Patrick Vizeli, Laura Ley, Felix Müller, Patrick Dolder, Melanie Stocker, Urs Duthaler, Nimmy Varghese, Anne Eckert, Stefan Borgwardt,[...]. Neuropsychopharmacology 2021
30
Neural correlates of the LSD experience revealed by multimodal neuroimaging.
Robin L Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E Schenberg, Timothy Nest, Csaba Orban,[...]. Proc Natl Acad Sci U S A 2016
Robin L Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo E Schenberg, Timothy Nest, Csaba Orban,[...]. Proc Natl Acad Sci U S A 2016
12
Psychedelics as Medicines: An Emerging New Paradigm.
D E Nichols, M W Johnson, C D Nichols. Clin Pharmacol Ther 2017
D E Nichols, M W Johnson, C D Nichols. Clin Pharmacol Ther 2017
12
The Current Status of Psychedelics in Psychiatry.
David Nutt, Robin Carhart-Harris. JAMA Psychiatry 2021
David Nutt, Robin Carhart-Harris. JAMA Psychiatry 2021
37
Effects of psilocybin therapy on personality structure.
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harris. Acta Psychiatr Scand 2018
18
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Frederick S Barrett, Manoj K Doss, Nathan D Sepeda, James J Pekar, Roland R Griffiths. Sci Rep 2020
Frederick S Barrett, Manoj K Doss, Nathan D Sepeda, James J Pekar, Roland R Griffiths. Sci Rep 2020
22
Psychedelic Psychiatry's Brave New World.
David Nutt, David Erritzoe, Robin Carhart-Harris. Cell 2020
David Nutt, David Erritzoe, Robin Carhart-Harris. Cell 2020
19
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
Javier González-Maeso, Noelia V Weisstaub, Mingming Zhou, Pokman Chan, Lidija Ivic, Rosalind Ang, Alena Lira, Maria Bradley-Moore, Yongchao Ge, Qiang Zhou,[...]. Neuron 2007
Javier González-Maeso, Noelia V Weisstaub, Mingming Zhou, Pokman Chan, Lidija Ivic, Rosalind Ang, Alena Lira, Maria Bradley-Moore, Yongchao Ge, Qiang Zhou,[...]. Neuron 2007
12
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H Preller, Franz X Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, Matthias E Liechti. Biol Psychiatry 2015
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H Preller, Franz X Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, Matthias E Liechti. Biol Psychiatry 2015
12
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.